NUTEX InvestmentsBUD:NUTEX -0.37%50 Net Margin % is 168,363.56% as of Dec. 2025, which is 3808% above its 10-year median of 4,308.22. GuruFocus rates BUD:NUTEX with a GF Score™ of 50/100 and a GF Value™ of Ft13.80 (Fairly Valued). The stock has 3 warning signs investors should review. Among 955 Drug Manufacturers companies, NUTEX Investments ranks better than 99.9% on this metric.
The historical rank and industry rank for NUTEX Investments's Net Margin % or its related term are showing as below:
BUD:NUTEX'
s Net Margin % Range Over the Past 10 Years
Min: -9096.42 Med: 4308.22 Max: 109815.78
Current: 109815.78
BUD:NUTEX's Net Margin % is ranked better than 99.9% of 955
companies
in the Drug Manufacturers industry
Industry Median: 5.69
vs BUD:NUTEX: 109815.78
NUTEX Investments (BUD:NUTEX) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
NUTEX Investments Net Margin % Related Terms
NUTEX Investments Net Margin % Historical Data
* Premium members only.
The historical data trend for NUTEX Investments's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BUD:NUTEX vs ZTS, UTHR, VTRS: Net Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, NUTEX Investments's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NUTEX Investments Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, NUTEX Investments's Net Margin % distribution charts can be found below:
* The bar in red indicates where NUTEX Investments's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NUTEX Investments (BUD:NUTEX) has a Net Margin % of 168,363.56% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on NUTEX Investments and its competitors. This is 3808% above median its historical median of 4,308.22. According to the industry distribution chart, NUTEX Investments ranks #1 out of 955 companies in the Drug Manufacturers industry, placing it in the top 0.099999999999994%.
Is NUTEX Investments' Net Margin % too high?
NUTEX Investments' current Net Margin % of 168,363.56% is 3808% above median its 10-year median of 4,308.22. The Drug Manufacturers industry median Net Margin % is 5.69. NUTEX Investments' value of 168,363.56% is 2958837.8% above this industry median. Based on the distribution chart, NUTEX Investments ranks #1 out of 955 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, NUTEX Investments has a GF Score™ of 50/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does NUTEX Investments' Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, NUTEX Investments ranks #1 out of 955 companies for Net Margin %. This places NUTEX Investments in the top 0% of its industry — outperforming the majority of peers. The industry median Net Margin % is 5.69. NUTEX Investments' value of 168,363.56% is 2958837.8% above this benchmark. While the company's 10-year median is 4,308.22 vs. the industry median of 5.69, NUTEX Investments has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.69, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NUTEX Investments's current Net Margin % of 168,363.56% is 2958837.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on NUTEX Investments and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NUTEX Investments's current Net Margin % is 168,363.56%, which is 3808% above median its own 10-year median of 4,308.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NUTEX Investments stock overvalued right now?
Based on GuruFocus' analysis, NUTEX Investments (BUD:NUTEX) is currently considered Fairly Valued. The stock's GF Value™ is Ft13.80, compared to a current price of Ft13.40 — trading 2.9% below its estimated fair value. The current Net Margin % is 168,363.56%, which is 3808% above median its 10-year median of 4,308.22 and 2958837.8% above the Drug Manufacturers industry median of 5.69. NUTEX Investments' overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For NUTEX Investments (BUD:NUTEX), the current Net Margin % is 168,363.56% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NUTEX Investments (BUD:NUTEX) Overvalued in 2026?
Based on GuruFocus' analysis, NUTEX Investments stock appears to be undervalued.
The current stock price of Ft13.40 is trading 2.9% below its estimated GF Value™ of Ft13.80.
GuruFocus considers NUTEX Investments to be Fairly Valued.
Key valuation signals for BUD:NUTEX:
Net Margin %: 168,363.56% (3808% above median its 10-year median of 4,308.22)
GF Value™: Ft13.80 vs. price of Ft13.40 (2.9% below fair value)
Industry Position: 2958837.8% above the Drug Manufacturers median (#1 of 955)
No single metric tells the full story. See the BUD:NUTEX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NUTEX Investments PLC operates as a drug manufacturer in Hungary. The company is engaged in production of products that focuses on health, vitality, and natural ingredients.
50GF Score
Get the complete analysis for BUD:NUTEX
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BUD:NUTEX has been successfully added to your 
